HARBIN, China, March 3 /Xinhua-PRNewswire-FirstCall/ -- China Sky One Medical, Inc. , a manufacturer, marketer and distributor of pharmaceutical, medicinal and diagnostic products in China, announced today the appointment of four new independent directors to its board -- including Song Chun Fang, Jiang Qi Feng, Zhao Jie and Qian Xu Feng. As a result, the number of directors has increased from three to seven. The changes were made in conjunction with the Company filing an application to list its shares on the American Stock Exchange.
Song Chun Fang, 68, has held various positions including Director of Surgery Research Room and Director of Graduate Students of the Surgery Department at the First Clinical College of Harbin Medical University in Heilongjiang, China since 1964. Additionally, he has served as the Acting Director of the Heilongjiang Professional Surgery Committee, Commissary of the Degree Commission of China, Director of Key Laboratory of Cell Transplantation of the Ministry of Public Health of China, Vice-Chairman of Heilongjiang Medicine Association, Vice-Chairman of Heilongjiang Physician Association, and Director of Heilongjiang (Special) Medical Treatment Application Administration Committee since 1998. He obtained his Bachelor’s degree in Medical Treatment from Harbin Medical University.
Jiang Qi Feng, 25, has served as Teaching Assistant and Research Assistant at Simon Fraser University since 2006. He obtained his Bachelor’s degree in Bio-Statistics and Mathematics from University of British Columbia, Canada, and his Masters degree in Computer Science from Simon Fraser University, Canada.
Zhao Jie, 45, has served as a Tissue Specialist at the Replant Department at Capital Health Transplant Services in Alberta, Canada since 1999. He obtained his Bachelor’s Degree in Medicine from Harbin Medical University.
Qian Xu Feng, 40, has held various roles including Vice President and Senior Analyst at Moody’s Investors Services since 2005. Previously, She was a Research Fellow at Furman Center for Real Estate and Urban Policy of New York University from 2004 to 2005, and Assistant Professor of Economics at Beijing Normal University from 1990 to 1996. She holds a Masters degree in Accounting from City University of New York, and a Bachelor’s Degree in Economics from Beijing Normal University. Additionally, she obtained his Masters and Ph.D. degrees in Economics from Rutgers University.
“China Sky One aims to achieve the highest standards of corporate governance as a U.S. listed public company. We look forward to working with our newly appointed independent board members to ensure that our company is able to fairly represent the interests of all our shareholders and look forward to their guidance as the company enters a new and exciting stage of our corporate development,” said Mr. Yan-qing Liu, Chairman, CEO and Director of China Sky One Medical, Inc. “In addition, we are very pleased to announce that we have applied to list our shares on the American Stock Exchange and believe that this will help contribute to improved marketability and liquidity for our common stock in the future.”
In addition, the Company has formed key committees of its board that will be held by its independent outside directors. The board members’ roles have been specified as the following: Qian Xu Feng, Jiang Qi Feng and Song Chun Fang will serve as members of the Company’s newly-formed Finance Committee; Song Chun Fang, Zhao Jie and Jiang Qi Feng will serve as members of the Company’s newly-formed Executive Committee; Zhao Jie, Qian Xu Feng and Song Chun Fang will serve as the members of the Company’s newly-formed Nominating and Governance Committee; Qian Xu Feng, Jiang Qi Feng and Song Chun Fang will serve as the members of the Company’s newly-formed Compensation Committee; and Jiang Qi Feng, Zhao Jie and Qian Xu Feng will serve as the members of the Company’s newly-formed Audit Committee.
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a Nevada corporation, is engaged in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic kit products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company (''TDR’’) and Harbin First Bio- Engineering Company Limited (“First”), the Company manufactures and distributes over-the- counter pharmaceutical products as its primary revenue source. For more information, visit http://www.skyonemedical.com .
Safe Harbor Statement
Certain of the statements made in the press release constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as “believe,” “expect,” “may,” “will,” “should,” “project,” “plan,” “seek,” “intend,” or “anticipate” or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding our future plans, objectives or performance. The Company cannot provide any assurance that its application to list on the American Stock Exchange will be approved or that the liquidity and marketability of its shares will improve. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the inability of the company to meet the listing standards, risks associated with the effect of changing economic conditions in The People’s Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.
tdrhan@163.comcrocker.coulson@ccgir.com
CONTACT: Ms. Xiaoyan Han, CFO of China Sky One Medical, Inc., +86-1335-
999-3681, or tdrhan@163.com; Or Mr. Crocker Coulson, President of CCG Elite
Investor Relations Inc., +1-646-213-1915 (New York), or
crocker.coulson@ccgir.com, for China Sky One Medical, Inc.
Web site: http://www.skyonemedical.com/
